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Abstract: There is some evidence that male gender could have a negative impact on the prognosis
and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of
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the present study was to compare the characteristics of coronavirus disease 2019 (COVID-19) between
hospitalized men and women with confirmed SARS-CoV-2 infection. This multicenter, retrospective,
observational study is based on the SEMI-COVID-19 Registry. We analyzed the differences between
men and women for a wide variety of demographic, clinical, and treatment variables, and the sex
distribution of the reported COVID-19 deaths, as well as intensive care unit (ICU) admission by age
subgroups. This work analyzed 12,063 patients (56.8% men). The women in our study were older
than the men, on average (67.9 vs. 65.7 years; p < 001). Bilateral condensation was more frequent
among men than women (31.8% vs. 29.9%; p = 0.007). The men needed non-invasive and invasive
mechanical ventilation more frequently (5.6% vs. 3.6%, p < 0.001, and 7.9% vs. 4.8%, p < 0.001,
respectively). The most prevalent complication was acute respiratory distress syndrome, with severe
cases in 19.9% of men (p < 0.001). In men, intensive care unit admission was more frequent (10% vs.
6.1%; p < 0.001) and the mortality rate was higher (23.1% vs. 18.9%; p < 0.001). Regarding mortality,
the differences by gender were statistically significant in the age groups from 55 years to 89 years of
age. A multivariate analysis showed that female sex was significantly and independently associated
with a lower risk of mortality in our study. Male sex appears to be related to worse progress in
COVID-19 patients and is an independent prognostic factor for mortality. In order to fully understand
its prognostic impact, other factors associated with sex must be considered.
Keywords: SARS-CoV-2; coronavirus; COVID-19; Spain; gender differences
1. Introduction
Since the first cases of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), were described in China in December
2019, this virus has spread worldwide. As of January 2021, there have been more than
94 million confirmed infections, and over 2 million deaths worldwide. It has a 2.2% fatality
rate [1–3].
Over 29.7 million infections have been recorded in Europe. In Spain, the first confirmed
SARS-CoV-2 infection was reported on 31 January 2020, and since then, Spain has been
one of the countries most affected by this pandemic, with 2,252,164 confirmed cases and
53,314 deaths as of 16 January 2021 [3,4].
The initial reports from China pointed to a difference in the number of cases detected
and the fatality rate between the sexes. However, few reports have addressed this disparity
in COVID-19 incidence and disease course according to sex; most of the studies that have
been published so far indicate that male gender is linked to more serious forms of the
disease, but more thorough investigation is necessary. As the disease has spread across
multiple countries, the Global Health 50/50, an independent research initiative for gender
equality, presented an overview of sex-disaggregated data from countries worldwide.
Though a similar numbers of cases have been recorded in women and men, the fatality
rate is higher among men; in January 2021, the number of COVID-19 deaths worldwide
was divided into approximately 777,000 men, 578,000 women, and 633,000 deaths for
which the sex was unknown. Nevertheless, sex-disaggregated data are still not provided
by all countries, and the number of cases and the case fatality rate vary significantly by
region [2,5,6].
In Spain, the Spanish Society of Internal Medicine (SEMI, for its initials in Spanish)
has sponsored the SEMI-COVID-19 Network. The SEMI-COVID-19 Registry involved
gathering detailed information on a large cohort of hospitalized patients. In this work,
statistical analyses were carried out on data on baseline characteristics, comorbidities,
clinical presentation, laboratory and radiological data, treatments received, clinical progress,
complications, the need for ICU admission, and in-hospital mortality [7].
The aim of this study was to analyze the differences in the clinical characteristics,
progress, and mortality rate of patients with COVID-19 according to sex. Understanding
sex-based differences in this disease is essential for the expansion of the knowledge of the
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etiopathogenesis and epidemiology of the virus, as well as to more precisely analyse the
social and economic impact that COVID-19 has on both patients and communities [1,8].
2. Materials and Methods
2.1. Study Design
This work is a multicenter, observational, cohort study of patients hospitalized due
to COVID-19 in Spain. The Spanish Society of Internal Medicine is the sponsor of the
nationwide SEMI-COVID-19 Registry, which retrospectively collects patient data. The
specific characteristics of the registry have been described in previous works [7].
2.2. Population and Inclusion Criteria
The SEMI-COVID-19 Registry included data on hospitalized patients over 18 years of
age with microbiologically-confirmed SARS-CoV-2 infection. All of the patients who were
discharged or deceased after hospital admission with confirmed SARS-CoV-2 infection
were candidates for inclusion. The infection was confirmed by a polymerase chain reaction
(PCR) test of a nasopharyngeal, sputum, or bronchoalveolar lavage sample, or a positive
result on a serological test with compatible symptoms.
In this work, the data on all of the patients in the registry were analyzed in order to
examine the differences between men and women. The inclusion criteria were: (a) an age
of 18 years or older; (b) a confirmed diagnosis of COVID-19; (c) a first hospital admission
to a Spanish hospital participating in the study, and (d) a hospital discharge or a hospital
death. The exclusion criteria were patients with incomplete data, and those who did not
provide consent.
The data analyzed included baseline characteristics, comorbidities, clinical and radio-
logical presentation, laboratory data, treatment, complications during hospitalization, and
in-hospital mortality.
This record began collecting patients in March 2020, and we are currently still collect-
ing data from hospitalized patients. The data in our study correspond to the first wave of
patients hospitalized by COVID from March 2020 until July 2020.
2.3. Ethical Aspects
The SEMI-COVID-19 Registry and the studies related to it were approved by the
Provincial Research Ethics Committee of Málaga (Spain). All of the included patients
or their legal representatives gave their informed consent. In cases in which there were
biological safety concerns, or in which the patient had already been discharged, consent
was obtained verbally and noted on the patient’s medical record.
2.4. Data Analysis
The patients were divided into two groups: a male group and a female group.
The normality of the continuous variable distributions was verified using the Kolmogorov–
Smirnov test. Data that follow a normal distribution are shown as means and standard
deviations (SD), whereas data that follow a non-normal distribution are shown as medians
and interquartile ranges (IQR). The comparisons between the groups for the normally
distributed continuous variables were made using Student’s t-test. In cases in which the
variables did not follow a normal distribution, the Mann-Whitney U test was used.
The categorical variables are expressed as absolute frequencies (n) and percentages
(%). In order to compare the categorical variables, we used the chi-square test or Fisher’s
exact test. The relationship between the variables and mortality was calculated using
a multivariate logistic regression model which included the variables of gender, age,
dependency, comorbidity, fever, dyspnea, confusion, tachypnea, severe acute respiratory
distress syndrome [ARDS], radiological affectation, and radiological worsening at 7 days.
Statistical significance was established as p < 0.05. The statistical analyses were
performed using SPSS version 25.0.
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3. Results
A total of 13,090 patients were included in the SEMI-COVID-19 Registry as of 2 June
2020. Of them, this work analyzed data on 12,063 patients, of which 6853 were men (56.8%).
Figure 1 shows the patient inclusion flowchart.
Figure 1. Patient inclusion flowchart.
3.1. General Data at Baseline
In our study population, the women were older than the men, with a mean age
of 67.9 vs. 65.7 years (p < 0.001). The notable findings on the baseline characteristics
and comorbidities include a higher smoking rate observed among men (6.9% vs. 3.3%;
p < 0.001) and a higher percentage of women with obesity (22.3% vs. 20.5%; p = 0.022).
Severe dependency was more frequent in women (10.1% vs. 5.1%; p < 0.001). All of the
data on the baseline characteristics and comorbidities are shown in Table 1.
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Table 1. Baseline characteristics and comorbidities of the study patients.
Male
n = 6853 (56.8%)
Female
n = 5210 (43.2%)
Total
n = 12063 p-Value
Age, mean (SD) 65.7 (15.8) 67.9 (16.9) 66.7 (16.3) <0.001
Smoker, n (%) 445 (6.9) 167 (3.3) 612 (5.3) <0.001
Obesity, n (%) 1265 (20.5) 1052 (22.3) 2317 (21.2) 0.022
Arterial hypertension, n (%) 3422 (50.0) 2636 (50.7) 6058 (50.3) 0.453
Dyslipidemia, n (%) 2699 (39.5) 2052 (39.5) 4751 (39.5) 0.997
Atrial fibrillation, n (%) 786 (11.5) 554 (10.7) 1340 (11.1) 0.145
Severe dependency, n (%) 346 (5.1) 516 (10.1) 862 (7.3) <0.001
Charlson Comorbidity Index, mean (SD) 3.57 (2.76) 3.59 (2.60) 3.58 (2.69) 0.729
Anxiety, n (%) 323 (4.7) 636 (12.3) 959 (8.0) <0.001
Depression, n (%) 418 (6.1) 844 (16.3) 1262 (10.5) <0.001
Neurodegenerative disease, n (%) 524 (7.7) 606 (11.7) 1130 (9.4) <0.001
Rare disease, n (%) 111 (1.6) 90 (1.7) 201 (1.7) <0.001
Dialysis, n (%) 79 (1.2) 43 (0.8) 122 (1.0) 0.109
SD: standard deviation.
3.2. Symptoms upon Admission
With regard to the clinical presentation of COVID-19, symptoms such as a cough,
fever > 38 ◦C, dyspnea, tachypnea and oxygen saturation < 92% were more frequent
among men, whereas milder symptoms such as odynophagia, ageusia, anosmia, arthralgia,
headache, and abdominal symptoms were more frequent among women.
On the chest X-rays, bilateral involvement was more common than unilateral in-
volvement. Bilateral condensation and bilateral interstitial infiltrates were significantly
more frequent in men (31.8% vs. 29.9%; p = 0.007 and 53.7% vs. 48.6%; p < 0.001, respec-
tively). Table 2 describes the clinical presentation of the COVID-19 disease, and the main
differences observed between the groups.
Table 2. Clinical presentation.
Male
n = 6853 (56.8)
Female
n = 5210 (43.2)
Total
n = 12,063 p-Value
Symptoms
Dry cough, n (%) 3996 (58.5) 3011 (58.1) 7007 (58.3)
<0.001
Productive cough, n (%) 1152 (16.9) 723 (13.9) 1875 (15.6)
Fever > 38◦, n (%) 4650 (68.1) 2976 (57.4) 7626 (63.5) <0.001
Ageusia, n (%) 414 (6.2) 381 (7.6) 795 (6.8) 0.005
Anorexia, n (%) 1267 (18.9) 1063 (20.9) 2330 (19.8) 0.008
Headache, n (%) 729 (10.8) 635 (12.4) 1364 (11.5) 0.007
Diarrhea, n (%) 1473 (21.7) 1285 (24.9) 2758 (23.1) <0.001
General malaise, n (%) 663 (9.9) 805 (15.9) 1468 (12.5) <0.001
Vomiting, n (%) 377 (5.6) 506 (9.9) 883 (7.4) <0.001
Abdominal pain, n (%) 376 (5.6) 402 (7.8) 778 (6.5) <0.001
Arthralgia, n (%) 2043 (30.2) 1610 (31.5) 3653 (30.8) 0.158
Anosmia, n (%) 385 (5.8) 331 (6.6) 716 (6.1) 0.089
Asthenia, n (%) 2878 (42.7) 2266 (44.4) 5144 (43.4) 0.072
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Table 2. Cont.
Male
n = 6853 (56.8)
Female
n = 5210 (43.2)
Total
n = 12,063 p-Value
Odynophagia, n (%) 631 (9.4) 531 (10.4) 1162 (9.8) 0.062
Dyspnea, n (%) 3971 (58.2) 2960 (57.2) 6931 (57.8) 0.265
Physical Examination
Confusion, n (%) 713 (10.6) 702 (13.7) 1415 (11.9) <0.001
Tachypnea, n (%) 2173 (32.6) 1505 (29.8) 3678 (31.4) 0.002
Hypotension (SBP < 100 mmHg), n (%) 358 (5.5) 331 (6.7) 689 (6.0) 0.006
Tachycardia (>100 bpm), n (%) 1502 (22.8) 1075 (21.5) 2577 (22.2) 0.103
Oxygen saturation < 92%, n (%) 2363 (35.6) 1569 (31.1) 3932 (33.6) <0.001
Wheezing, n (%) 355 (5.3) 359 (7.1) 714 (6.1) <0.001
Rales, n (%) 757 (11.4) 517 (10.2) 1274 (10.9) 0.045
Crackles, n (%) 3504 (52.8) 2648 (52.4) 6157 (52.7) 0.666
Radiological Data
Unilateral condensation, n (%)









Unilateral interstitial infiltrates, n (%)









Unilateral pleural effusion, n (%)









Radiological worsening *, n (%) 2255 (43.6) 1343 (35.9) 3598 (40.4) <0.001
Laboratory Data
Lymphocytes < 1500/mm3, n (%) 5771 (84.8) 4101 (79.9) 9872 (82.7) <0.001
LDH > 300 IU/L, n (%) 3377 (56.9) 2255 (51.1) 5632 (54.4) <0.001
D-Dimer > 500 ng/mL, n (%) 3148 (59.7) 2417 (61.5) 5565 (60.4) 0.084
* Radiological worsening at follow-up at 7 days, discharge, or death. LDH: lactate dehydrogenase; SBP: systolic blood pressure. bpm: beats
per min. mmHg: millimeters of mercury.
3.3. Treatments
The data regarding the treatment received were also analyzed. Systemic steroids were
widely used, with higher frequency among men, a finding that was statistically significant
(38.7% vs. 30.5%; p < 0.001). Men required non-invasive mechanical ventilation (NIVM)
and invasive mechanical ventilation (IMV) more frequently than women (5.6% vs. 3.6%,
p < 0.001, and 7.9% vs. 4.8%, p < 0.001, respectively). Oxygen via high-flow nasal cannula
was also used more frequently in men (9.4% vs. 7.2%, p < 0.001) and prone positioning
was used in 12.5% of men and 7.2% of women (p < 0.001). Full anticoagulant doses of
low-molecular-weight heparin (LMWH) were more frequently administered in the male
group (11.8% vs. 9.0%; p < 0.001). The complete data on the treatments, including the other
types of treatments prescribed during hospitalization, can be seen in Table 3.
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Table 3. Treatment during admission.
Male
n = 6853 (56.8)
Female
n = 5210 (43.2)
Total
n = 12,063 p-Value
Most Used Treatments
Hydroxychloroquine, n (%) 5931 (86.9) 4353 (84.1) 10,284 (85.7) <0.001
Lopinavir/ritonavir, n (%) 4438 (65.1) 2954 (57.1) 7392 (61.7) <0.001
Remdesivir, n (%) 42 (0.6) 16 (0.3) 58 (0.5) 0.016
Interferon beta-1B, n (%) 943 (13.9) 481 (9.4) 1424 (11.9) <0.001
Tocilizumab, n (%) 738 (10.9) 324 (6.3) 1062 (8.9) <0.001
Systemic steroids, n (%) 2632 (38.7) 1571 (30.5) 4203 (35.2) <0.001
Chloroquine, n (%) 313 (4.6) 215 (4.2) 528 (4.4) 0.243
Colchicine, n (%) 60 (0.9) 45 (0.9) 105 (0.9) 0.959
Immunoglobulins, n (%) 35 (0.5) 15 (0.3) 50 (0.4) 0.061
Anakinra, n (%) 45 (0.7) 15 (0.3) 60 (0.5) 0.005
Baricitinib, n (%) 29 (0.6) 11 (0.1) 40 (0.3) 0.043
Oseltamivir, n (%) 66 (1.0) 36 (0.7) 102 (0.9) 0.109
Inhaled beclomethasone, n (%) 390 (5.8) 284 (5.6) 674 (5.7) 0.593
Antibiotics
Beta-lactams, n (%) 5188 (76.2) 3642 (70.4) 8830 (73.7) <0.001
Macrolides, n (%) 4223 (62.1) 3013 (58.4) 7236 (60.0) <0.001
Quinolones, n (%) 894 (13.3) 645 (12.6) 1539 (13.0) 0.268
Respiratory Therapies
NIMV, n (%) 384 (5.6) 187 (3.6) 571 (4.8) <0.001
IMV, n (%) 541 (7.9) 249 (4.8) 790 (6.6) <0.001
High flow nasal cannula, n (%) 640 (9.4) 368 (7.2) 1008 (8.5) <0.001
Prone positioning, n (%) 851 (12.5) 370 (7.2) 1221 (10.2) <0.001
Other Treatments During Admission
ACEI, n (%) 672 (9.9) 421 (8.2) 1093 (9.2) 0.001
ARB, n (%) 703 (10.4) 535 (10.4) 1238 (10.4) 0.965
ASA, n (%) 962 (14.3) 581 (11.4) 1543 (13.1) <0.001
Statins, n (%) 967 (14.4) 642 (12.6) 1609 (13.6) 0.005










LMWH: Prophylactic doses, n (%)
LMWH: Full anticoagulant doses, n (%)























NIMV: non-invasive mechanical ventilation; IMV: invasive mechanical ventilation; ACEI: angiotensin converting enzyme inhibitors;
ARB: angiotensin ii receptor blockers; ASA: acetylsalicylic acid; DOAC: direct oral anticoagulant; LMWH: low molecular weight heparin;
NSAIDs: nonsteroidal anti-inflammatory drugs.
3.4. Outcomes
Regarding complications during hospitalization, men suffered more complications.
Acute respiratory distress syndrome (ARDS) was the most common complication, and
severe ARDS was more frequently in men (19.9% vs. 14%, p < 0.001). Men needed ICU
admission more often than women (10% vs. 6.1%, p < 0.001), and presented higher in-
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hospital mortality (23.1% vs. 18.9%, p < 0.001). Table 4 details the data on complications
during admission, ICU admission, and in-hospital mortality.
Table 4. Complications, ICU admission rate, and in-hospital mortality.
Male
n = 6853 (56.8%)
Female
n = 5210 (43.2%)
Total
n = 12,063 p-Value
Complications
ARDS mild, n (%)
ARDS moderate, n (%)













Acute kidney injury, n (%) 1082 (15.9) 609 (11.8) 1691 (14.1) <0.001
Bacterial pneumonia, n (%) 806 (11.9) 480 (9.3) 1286 (10.8) <0.001
Multi-organic failure, n (%) 505 (7.4) 252 (4.9) 757 (6.3) <0.001
Sepsis, n (%) 481 (7.1) 267 (5.2) 748 (6.3) <0.001
Shock, n (%) 366 (5.4) 173 (3.4) 539 (4.5) <0.001
DIC, n (%) 89 (1.3) 41 (0.8) 130 (1.1) 0.007
Acute myocardial infarction, n (%) 67 (1.0) 28 (0.5) 95 (0.8) 0.007
Peripheral arterial disease, n (%) 43 (0.6) 13 (0.3) 56 (0.5) 0.003
Heart failure, n (%) 398 (5.9) 333 (6.5) 731 (6.1) 0.176
Atrial arrhythmia, n (%)









Myocarditis, n (%) 74 (1.1) 43 (0.8) 117 (1.0) 0.159
Seizures, n (%) 38 (0.3) 34 (0.3) 72 (0.6) 0.484
Ischemic stroke, n (%)









VTE: DVT, n (%)
VTE: PE, n (%)













ICU Admission Rate and in-Hospital Mortality
ICU admission, n (%) 684 (10.0) 318 (6.1) 1002 (8.3) <0.001
In-hospital mortality, n (%) 1547 (23.1) 962 (18.9) 2509 (21.3) <0.001
ARDS: acute respiratory distress syndrome; DIC: disseminated intravascular coagulation; VTE: venous thromboembolism; DVT: deep vein
thrombosis; PE: pulmonary embolism.
We analyzed the age and sex distribution of the reported COVID-19 deaths in our
study, as well as ICU admission by age subgroups. A complete picture of the results can
be seen in Figures 2 and 3. In both data sets, men have a higher mortality and income
rate in the ICU. Most of the deceased were over 85 years of age, in both groups, men
and women (52.2% vs. 41.2%, p < 0.001). It is important that when we compare the
graphs, the percentages should be related to the size of the population in each subgroup,
since it is notable that, as age increases, the gender gap is more noticeable despite the
fact that women are in the majority in the upper age groups, and—in our study—also
present greater dependence than men. Regarding mortality, the differences by gender are
statistically significant in the age groups from 55 years to 89. If we take into account the
ICU admissions, the differences are significant from 45 to 74 years, except in the age group
of 50 to 54 years. It is important to note that the age group with the greatest difference with
a great statistical significance is that of 70 to 74 years (15% vs. 8.3%, p < 0.001).
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Figure 2. Mortality between the sexes according to age range.
Figure 3. Intensive Care Unit (ICU) admission by sex and age range.
3.5. Risk Factors for Mortality
A multivariate analysis was conducted in order to analyze the associations between
some of the aforementioned variables and mortality. The variables of age, moderate and
severe dependence, a Charlson comorbidity index above 3 points, confusion, tachypnea,
radiological worsening at seven days, and severe acute respiratory distress syndrome were
independently associated with higher mortality in the multivariate analysis. Therefore,
our analysis shows that female sex was significantly and independently associated with a
lower risk of mortality in the patients admitted for SARS-COV-2 infection (Hazard Ratio
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(HR) 0.771; confidence interval (CI) 95% 0.642-0925, p = 0.005). In this analysis, fever,
dyspnea, and bilateral radiological involvement were not shown to be independent factors
of mortality. Table 5 details the multivariate analysis of the selected variables in relation to
mortality.
Table 5. Independent variables associated with in-hospital death.
Mortality Univariate Analysis Multivariate Analysis
HR (CI 95%) p-Value HR (CI 95%) p-Value
Gender (female) 0.777 (0.710–0.851) <0.001 0.771 (0.642–0.925) 0.005











Charlson Comorbidity Index < 3 points 9.759 (8.668–10.988) <0.001 3.431 (2.673–4.403) <0.001
Fever > 38 ◦C 0.812 (0.727–0.907) <0.001 0.907 (0.724–1.135) 0.393
Dyspnea 2.097 (1.095–2.308) <0.001 1.173 (0.968–1.422) 0.104
Confusion 6.321 (5.619–7.111) <0.001 2.264 (1.781–2.877) <0.001
Tachypnea > 20 bpm 4.049 (3.687–4.446) <0.001 1.321 (1.096–1.592) 0.003
Severe ARDS 4.757 (4.015–5.638) <0.001 7.942 (6.084–10.366) <0.001
Bilateral pneumonia 1.386 (1.216–1.579) <0.001 1.168 (0.898–1.519) 0.247
Radiological worsening at 7 days of hospitalization 5.003 (4.424–5.658) <0.001 2.352 (1.956–2.828) <0.001
ARDS: acute respiratory distress syndrome.
4. Discussion
Since the onset of the COVID-19 pandemic, and since the first studies on the disease
were conducted, a greater vulnerability to the disease and its complications, as well as a
higher mortality rate, have been observed in men compared to women. Along these lines,
this work has found that men with COVID-19 had complications more often, had a higher
rate of ICU admission, and had a higher mortality rate compared to women.
Our data coincide with those reported in other studies. In Italy, a study comparing
different variables that analyzed the effect of COVID-19 on daily deaths per 100,000 people
of all genders and ages showed 30% higher mortality in men compared to women, with this
difference becoming notably more striking in those aged 60 years and older. Worldwide, it
is estimated that twice as many men die due to COVID-19 than women, according to data
from the European Center for Disease Prevention and Control [9,10].
In the UK, researchers at the Intensive Care National Audit and Research Centre
analyzed a sample of 7542 critically ill patients with confirmed COVID-19 and found that
5389 of these patients were men and 2140 were women. They also found that men were
more likely to die in the ICU, with 51% of the men who were admitted dying compared to
43% of the women [11].
One of the first studies on the differences between men and women with COVID-19
was a retrospective analysis of 168 patients, which evaluated the differences between
the clinical characteristics of critically ill patients according to sex. Again, its age- and
comorbidity-adjusted results also found higher mortality and a worse prognosis among
men [12].
In a recent meta-analysis on COVID-19, the authors confirmed the higher mortality
of men over women. They placed particular importance on external factors that could
contribute to this increase in deaths, especially in terms of habits and lifestyles. For example,
one of the works included was a Chinese study in which the prevalence of smoking among
men was ten times higher than that in women, which could have a negative impact on
their health status. This could therefore entail a prior deteriorated health status that could
condition greater severity of infection in men [13,14].
In our work, it is striking that even though the women in the study were older than
the men, and had a higher percentage of severe dependence, coupled with the fact that
both groups had similar percentages of comorbidities, the men had greater mortality and
a higher number of ICU admissions. However, it is true that the men arrived at our
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hospital in worse condition and with more serious symptoms than the women, and a
greater percentage of the men had established bilateral pneumonia upon admission.
Another important finding of our work concerns the differences in the treatments
received according to sex. A greater use of systemic treatments and respiratory therapies
was observed in the male group compared to the female group. In regard to this finding,
we hypothesize that the men in our study were younger than the women, and thus had a
higher life expectancy; therefore, they may have been administered more treatments.
Alternatively, another explanation for why men had worse clinical progress than
women may be due to reasons that are not yet clearly defined.
It is important to note, in our study, that the differences in mortality in terms of
gender are greater and statistically significant according to the older age of the patients.
Thus, we find similar data in the literature, as in a study with a sample of patients in New
York, in which increasing age and male sex are independent factors associated with worse
in-hospital evolution [15].
In another study carried out with a sample of Italian patients, the authors concluded
that men from the age of 50 and women from the age of 80 had a worse prognosis in terms
of radiological evolution (although the sample of men was almost three times larger than
that of women), and if we look at the data of our study, in men, the percentage of higher
mortality begins to be notably different from the other age ranges after 55 years, and in
women after 75 years, which could overlap with the conclusions of the Italian study [16].
A meta-analysis that included 60 studies and more than 50,000 patients found that
age played an important role in the analysis by subgroups, as although advanced age
supposes an independent risk of mortality or worse prognosis, if other factors were taken
into account, such as smoking or dyspnea on admission, mortality was higher in younger
patient groups, and they concluded that these two factors are associated with a worse
prognosis in populations with less exposure to the main risk factors for mortality from
COVID-19, that is, elderly patients, a high proportion of men, and a high prevalence of
comorbidities [17].
In another study with Canadian patients, they compared differences between women
and men in different age groups in terms of hospital admission, ICU admission, time
to recovery, and mortality, and found that there were large differences in women under
30 years of age and men of the same age in terms of hospitalization and admission to the
ICU, and observed that, from the age of 60, there was a significant decrease in mortality in
women compared to men of the same age group. They concluded that estrogens in women
after puberty and before menopause could play a fundamental role, and that there may
be a possible mechanism between estrogen levels and mortality/time to recovery that is
not yet well defined, although in women aged over 60 years there would have to be other
additional factors [18].
In China, in a study of 80,000 patients, patients older than 60 years had a 9.9 times
greater risk of dying than patients younger than 30 years. Regarding the differences by
gender, women presented less severity of the disease in all age ranges except those between
20 and 29 years. Regarding mortality, in all age groups, it was lower in women, with this
difference being statistically significant from 30 years [19].
In another meta-analysis with 59 studies and more than 36,000 patients included, men
demonstrated more severe forms of SARS-CoV-2 disease than women in all age groups.
In addition, men had a higher ICU admission and mortality rate than women. In this
meta-analysis, patients in both groups (men and women) older than 70 years had a worse
prognosis, higher mortality, and a higher rate of admission to the ICU than those younger
than 70 years [20].
Another interesting study on laboratory hematological parameters in COVID-19
infection suggests that it is important to carry out studies that analyze the differences in
these parameters between men and women, as these results could be valuable to determine
why the disease manifests itself in men more seriously than in women. In our study, men
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had higher lymphopenia and higher lactate dehydrogenase (LDH) and D-dimer levels,
with these results being statistically significant [21].
This leads us to wonder whether men have worse progress solely due to their sex, or
whether there are other intervening factors. Some possible factors can be observed in the
multivariate analysis conducted in this study, such as older age, radiological worsening
at seven days, and confusion at the onset of the disease. Indeed, our data show that men
develop more symptoms—such as a cough, fever, and tachypnea—at the onset of the
disease than women.
Delving deeper into the influence that comorbidities and lifestyle can have on COVID-
19 infection according to gender, one study in the literature examined the differences
between females and males among COVID-19 patients in China. In this work, the men
were more likely than the women to have two or more major comorbidities. Of those with
COVID-19 and chronic obstructive pulmonary disease, 83.3% were men. Males represented
58.9% of those with diabetes, and 62.1% of those with some type of cardiovascular disease.
Several studies have shown that, in places where mortality is higher in men than in women,
men largely show behaviors that can worsen health, such as smoking, poor diet, or a
sedentary lifestyle, along with their related comorbidities. Indeed, in our study, more men
were smokers than women. An analysis of other lifestyle factors that were not assessed in
our registry would be an interesting future line of research [22–24].
Finally, there are studies that attempt to explain this bias between men and women
according to physiopathogenesis and innate characteristics of biological sex. In the litera-
ture consulted, we found several articles that defend the notion that women have a better
immune response to external pathogens, and many of the genes that regulate this immune
response are found on the X chromosome. Hormones could also play a fundamental role;
estrogens could be beneficial in improving the immune response, as they enhance the
proliferation of T lymphocytes and attenuate the cytokine storm, while testosterone in men
could have a certain negative effect [25,26].
Another study by Haitao et al. on the mechanisms by which biological sex can influ-
ence the prognosis of COVID-19 disease concluded that the greater severity and mortality
in men compared to women is most likely due to a combination of factors: on the one hand,
differences regarding behavior and lifestyles and, on the other hand, comorbidities that
affect men to a greater extent. They conclude that biological sex differences could affect
the risk of contracting the disease, its physiopathogenic mechanisms, and its severity due
to, among other causes, the fact that men are more likely to develop the dreaded cytokine
storm associated with a higher lethality of the virus [27].
Another possible explanation is that sex differences in COVID-19 could be related to
different angiotensin converting enzyme 2 (ACE2) receptor expression, as several studies
have shown a greater presence of ACE2 receptor receptors in the Leydig cells and kidneys
of men due to mechanisms possibly explained by hormonal differences. This is why diffuse
alveolar damage is the main cause of morbidity and mortality in SARS-CoV-2 infection.
Older age is also related to a higher expression of ACE2 receptors, although a greater
number of specific studies are necessary in order to be able to develop a definitive theory. A
study that began before the COVID-19 pandemic which aimed to investigate patients with
heart failure and ACE2 found that men, older patients, and those with more comorbidities
had higher concentrations of ACE2. These results were validated with another control
group of more than 2000 patients. It was suggested that, perhaps, this was the reason
why men are more susceptible to contracting the infection and presenting with worsening
symptoms than women [26,28].
The data in this study are from the ‘first wave’ of contagions in Spain. Today, the
SARS-CoV-2 epidemic continues to progress exponentially, and it is necessary to learn
from past mistakes in order to improve the treatment of this disease. It is clear that some
gender-related aspects—such as comorbidities or lifestyle choices like active smoking,
which are more common among males—refuted in our study may play a key role in the
higher percentage of ICU admission and higher mortality of men compared to women,
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although other circumstances related to biological sex that are not analyzed in our registry
should be taken into account as possible endpoints in future studies.
The strength of this study is that it is a multicenter study which included a large
number of patients. On the other hand, there are limitations, as statistically more complete
and advanced studies with larger sample sizes are required due to the overwhelming
incidence of the disease. Furthermore, the retrospective nature of the study, and the fact
that the vast majority of the patients in this study were Caucasian, that all required hospital
admission, and the unknown real spread of COVID-19 among outpatients, mean that our
results cannot be easily extrapolated to the general population.
5. Conclusions
Male sex seems to be related to worse progress in the SARS-CoV-2 disease. Men
present with more symptoms at the disease’s onset, have more complications during hospi-
talization, require a greater number of treatments, are more frequently admitted to the ICU,
and have a higher mortality rate. Male sex and older age seem to be independent prognos-
tic factors for mortality, but—in order to fully understand its impact on the prognosis of
the disease—we must always consider other factors associated with sex.
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Andrés González García, Oscar Alberto López Cisneros, Luis Manzano, Miguel Martínez-
Lacalzada, Borja Merino Ortiz, Jimena Rey-García, Elisa Riera González, Cristina Sánchez
Díaz, Grisell Starita Fajardo, Cecilia Suárez Carantoña, Adrian Viteri-Noël, Svetlana Zhilina
Zhilina.
H. U. San Juan de Alicante. San Juan de Alicante
Marisa Asensio Tomás, David Balaz, David Bonet Tur, Ruth Cañizares Navarro,
Paloma Chazarra Pérez, Jesús Corbacho Redondo, Eliana Damonte White, Leticia Espinosa
Del Barrio, Pedro Jesús Esteve Atiénzar, Carles García Cervera, David Francisco García
Núñez, Vicente Giner Galvañ, Angie Gómez Uranga, Javier Guzmán Martínez, Isidro
Hernández Isasi, Lourdes Lajara Villar, Verónica Martínez Sempere, Juan Manuel Núñez
Cruz, Sergio Palacios Fernández, Juan Jorge Peris García, Andrea Riaño Pérez, José Miguel
Seguí Ripoll, Azucena Sempere Mira, Philip Wikman-Jorgensen.
H. Virgen de la Salud. Toledo
Ana Maria Alguacil Muñoz, Marta Blanco Fernández, Veronica Cano, Ricardo Crespo
Moreno, Fernando Cuadra Garcia-Tenorio, Blanca Díaz-Tendero Nájera, Raquel Estévez
González, María Paz García Butenegro, Alberto Gato Díez, Verónica Gómez Caverzaschi,
Piedad María Gómez Pedraza, Julio González Moraleja, Raúl Hidalgo Carvajal, Patricia
Jiménez Aranda, Raquel Labra González, Áxel Legua Caparachini, Pilar Lopez Castañeyra,
Agustín Lozano Ancin, Jose Domingo Martin Garcia, Cristina Morata Romero, María
Jesús Moya Saiz, Helena Moza Moríñigo, Gemma Muñiz Nicolás, Enriqueta Muñoz Platon,
Filomena Oliveri, Elena Ortiz Ortiz, Raúl Perea Rafael, Pilar Redondo Galán, María Antonia
Sepulveda Berrocal, Vicente Serrano Romero de Ávila, Pilar Toledano Sierra, Yamilex
Urbano Aranda, Jesús Vázquez Clemente, Carmen Yera Bergua.
Hospital Regional Universitario de Málaga. Málaga
Ma Mar Ayala-Gutiérrez, Rosa Bernal López, José Bueno Fonseca, Verónica An-
drea Buonaiuto, Luis Francisco Caballero Martínez, Lidia Cobos Palacios, Clara Costo
Muriel, Francis de Windt, Ana Teresa Fernandez-Truchaud Christophel, Paula García
Ocaña, Ricardo Gómez Huelgas, Javier Gorospe García, Sergio Jansen-Chaparro, Maria
Dolores López-Carmona, Pablo López Quirantes, Almudena López Sampalo, Elizabeth
Lorenzo-Hernández, Juan José Mancebo Sevilla, Jesica Martín Carmona, Luis Miguel Pérez-
Belmonte, Iván Pérez de Pedro, Araceli Pineda-Cantero, Carlos Romero Gómez, Michele
Ricci, Jaime Sanz Cánovas.
H. Santa Marina. Bilbao
Maria Areses Manrique, Ainara Coduras Erdozain, Ane Labirua-Iturburu Ruiz.
H. Juan Ramón Jiménez. Huelva
Francisco Javier Bejarano Luque, Francisco-Javier Carrasco-Sánchez, Mercedes de-
Sousa-Baena, Jaime Díaz Leal, Aurora Espinar Rubio, Maria Franco Huertas, Juan An-
tonio García Bravo, Andrés Gonzalez Macías, Encarnación Gutiérrez Jiménez, Alicia Hi-
dalgo Jiménez, Constantino Lozano Quintero, Carmen Mancilla Reguera, Francisco Javier
Martínez Marcos, Francisco Muñoz Beamud, Maria Pérez-Aguilar, Alícia Pérez Jiménez,
Virginia Rodríguez Castaño, Alvaro Sánchez de Alcazar del Río, Leire Toscano Ruiz.
H. del Henares. Coslada
Jesús Ballano Rodríguez-Solís, Luis Cabeza Osorio, María del Pilar Fidalgo Montero,
Ma Isabel Fuentes Soriano, Erika Esperanza Lozano Rincon, Ana Martín Hermida, Jesus
Martinez Carrilero, Jose Angel Pestaña Santiago, Manuel Sánchez Robledo, Patricia Sanz
Rojas, Nahum Jacobo Torres Yebes, Vanessa Vento.
H. U. La Fe. Valencia
J. Clin. Med. 2021, 10, 899 18 of 21
Dafne Cabañero, María Calabuig Ballester, Pascual Císcar Fernández, Ricardo Gil
Sánchez, Marta Jiménez Escrig, Cristina Marín Amela, Laura Parra Gómez, Carlos Puig
Navarro, José Antonio Todolí Parra.
Complejo Hospitalario Universitario Ourense. Ourense
Raquel Fernández González, Amara Gonzalez Noya, Carlos Hernández Ceron, Isabel
Izuzquiza Avanzini, Ana Latorre Diez, Pablo López Mato, Ana María Lorenzo Vizcaya,
Daniel Peña Benítez, Milagros María Peña Zemsch, Lucía Pérez Expósito, Marta Pose Bar,
Lara Rey González, Laura Rodrigo Lara
H. de Mataró. Mataró
Raquel Aranega González, Ramon Boixeda, Javier Fernández Fernández, Carlos
Lopera Mármol, Marta Parra Navarro, Ainhoa Rex Guzmán, Aleix Serrallonga Fustier.
H. U. Reina Sofía. Córdoba
Antonio Pablo Arenas de Larriva, Pilar Calero Espinal, Javier Delgado Lista, Francisco
Fuentes-Jiménez, María Jesús Gómez Vázquez, Jose Jiménez Torres, Laura Limia Pérez,
José López-Miranda, Laura Martín Piedra, Marta Millán Orge, Javier Pascual Vinagre,
Pablo Pérez-Martinez, María Elena Revelles Vílchez, Angela Rodrigo Martínez, Juan Luis
Romero Cabrera, José David Torres-Peña.
C. H. U. de Badajoz. Badajoz
Rafael Aragon Lara, Inmaculada Cimadevilla Fernandez, Juan Carlos Cira García,
Gema Maria García García, Julia Gonzalez Granados, Beatriz Guerrero Sánchez, Francisco
Javier Monreal Periáñez, Maria Josefa Pascual Perez.
H. U. Son Llàtzer. Palma de Mallorca
Andrés de la Peña Fernández, Almudena Hernández Milián
H. U. Río Hortega. Valladolid
Irene Arroyo Jiménez, Marina Cazorla González, Marta Cobos-Siles, Luis Corral-
Gudino, Pablo Cubero Morais, María González Fernández, José Pablo Miramontes González,
Marina Prieto Dehesa, Pablo Sanz Espinosa.
Hospital Alto Guadalquivir. Andújar
Begoña Cortés Rodríguez.
Hospital Infanta Margarita. Cabra
María Esther Guisado Espartero, Lorena Montero Rivas, Maria de la Sierra Navas
Alcántara, Raimundo Tirado-Miranda.
C. H. U. de Ferrol. Ferrol
Hortensia Alvarez Diaz, Tamara Dalama Lopez, Estefania Martul Pego, Carmen Mella
Pérez, Ana Pazos Ferro, Sabela Sánchez Trigo, Dolores Suarez Sambade, Maria Trigas
Ferrin, Maria del Carmen Vázquez Friol, Laura Vilariño Maneiro.
H. de Pozoblanco. Pozoblanco
José Nicolás Alcalá Pedrajas, Antonia Márquez García, Inés Vargas.
Hospital Marina Baixa. Villajoyosa
Javier Ena, Jose Enrique Gómez Segado.
H. U. Virgen de las Nieves. Granada
Pablo Conde Baena, Joaquin Escobar Sevilla, Laura Gallo Padilla, Patricia Gómez
Ronquillo, Pablo González Bustos, María Navío Botías, Jessica Ramírez Taboada, Mar
Rivero Rodríguez.
Hospital del Tajo. Aranjuez
Ruth Gonzalez Ferrer, Virginia Gracia Lorenzo, Raquel Monsalvo Arroyo.
Hospital Doctor José Molina Orosa. Arrecife (Lanzarote)
Virginia Herrero García, Berta Román Bernal.
H. U. Marqués de Valdecilla. Santander
Marta Fernández-Ayala Novo, José Javier Napal Lecumberri, Nuria Puente Ruiz, Jose
Riancho, Isabel Sampedro Garcia.
H. U. Severo Ochoa. Leganés
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Yolanda Casillas Viera, Lucía Cayuela Rodríguez, Carmen de Juan Alvarez, Gema
Flox Benitez, Laura García Escudero, Juan Martin Torres, Patricia Moreira Escriche, Susana
Plaza Canteli, M Carmen Romero Pérez.
H. General Defensa. Zaragoza
Anyuli Gracia Gutiérrez, Leticia Esther Royo Trallero
Hospital Platón. Barcelona
Ana Suarez Lombraña
Hospital Valle del Nalón. Riaño (Langreo)
Sara Fuente Cosío, César Manuel Gallo Álvaro, Julia Lobo García, Antía Pérez Piñeiro.
H. U. del Vinalopó. Elche
Francisco Amorós Martínez, Erika Ascuña Vásquez, José Carlos Escribano Stablé,
Adriana Hernández Belmonte, Ana Maestre Peiró, Raquel Martínez Goñi, M.Carmen
Pacheco Castellanos, Bernardino Soldan Belda, David Vicente Navarro.
H. G. U. de Castellón. Castellón de la Plana
Jorge Andrés Soler, Marián Bennasar Remolar, Alejandro Cardenal Álvarez, Daniela
Díaz Carlotti, María José Esteve Gimeno, Sergio Fabra Juana, Paula García López, María
Teresa Guinot Soler, Daniela Palomo de la Sota, Guillem Pascual Castellanos, Ignacio Pérez
Catalán, Celia Roig Martí, Paula Rubert Monzó, Javier Ruiz Padilla, Nuria Tornador Gaya,
Jorge Usó Blasco.
H. G. U. de Elda. Elda
Carmen Cortés Saavedra, Jennifer Fernández Gómez, Borja González López, María
Soledad Hernández Garrido, Ana Isabel López Amorós, Santiago López Gil, Maria de los
Reyes Pascual Pérez, Nuria Ramírez Perea, Andrea Torregrosa García
C. A. U. de Salamanca. Salamanca
Gloria María Alonso Claudio, Víctor Barreales Rodríguez, Cristina Carbonell Muñoz,
Adela Carpio Pérez, María Victoria Coral Orbes, Daniel Encinas Sánchez, Sandra Inés
Revuelta, Miguel Marcos Martín, José Ignacio Martín González, José Ángel Martín Oterino,
Leticia Moralejo Alonso, Sonia Peña Balbuena, María Luisa Pérez García, Ana Ramon
Prados, Beatriz Rodríguez-Alonso, Ángela Romero Alegría, Maria Sanchez Ledesma, Rosa
Juana Tejera Pérez.
Hospital de Palamós. Palamós
Ana Alberich Conesa, Mari Cruz Almendros Rivas, Miquel Hortos Alsina, José
Marchena Romero, Anabel Martin-Urda Diez-Canseco.
H. Santa Bárbara. Soria
Marta León Téllez.
H. U. del Sureste. Arganda del Rey
Jon Cabrejas Ugartondo, Ana Belén Mancebo Plaza, Arturo Noguerado Asensio,
Bethania Pérez Alves, Natalia Vicente López.
H. Parc Tauli. Sabadell
Francisco Epelde, Isabel Torrente
H. U. Quironsalud Madrid. Pozuelo de Alarcón (Madrid)
Pablo Guisado Vasco, Ana Roda Santacruz, Ana Valverde Muñoz.
Hospital Público de Monforte de Lemos. Monforte de Lemos
José López Castro, Manuel Lorenzo López Reboiro, Cristina Sardiña González.
H. U. Lucus Augusti. Lugo
Raquel Gómez Méndez, Ana Rodríguez Álvarez.
H. Virgen de los Lirios. Alcoy (Alicante)
Ma José Esteban Giner.
Hospital Clínico Universitario de Valladolid. Valladolid
Xjoylin Teresita Egües Torres, Sara Gutiérrez González, Cristina Novoa Fernández,
Pablo Tellería Gómez.
Hospital do Salnes. Vilagarcía de Arousa
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Vanesa Alende Castro, Ana María Baz Lomba, Ruth Brea Aparicio, Marta Fernández
Morales, Jesús Manuel Fernández Villar, María Teresa López Monteagudo, Cristina Pérez
García, Lorena Rodríguez Ferreira, Diana Sande Llovo, Maria Begoña Valle Feijoo.
H. de la Axarquía. Vélez- Málaga
Antonio López Ruiz.
H. Virgen del Mar. Madrid
Thamar Capel Astrua, Paola Tatiana Garcia Giraldo, Maria Jesús González Juárez,
Victoria Marquez Fernandez, Ada Viviana Romero Echevarry.
H. Comarcal de Blanes. Blanes
Oriol Alonso Gisbert, Mercé Blázquez Llistosella, Pere Comas Casanova, Angels
Garcia Flores, Anna Garcia Hinojo, Ana Inés Méndez Martínez, Maria del Carmen Nogales
Nieves, Agnés Rivera Austrui, Alberto Zamora Cervantes.
H. U. HM Montepríncipe. Madrid
Jose F. Varona
Hospital Quironsalud A Coruña. A Coruña
Hector Meijide Miguez
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